SELENOM (Selenoprotein M) is a member of the selenoprotein family, characterized by the incorporation of selenocysteine (Sec) at its active site. It is primarily localized in the endoplasmic reticulum and plays roles in redox homeostasis, calcium regulation, and cellular stress responses. SELENOM has been implicated in various physiological and pathological processes, including neuroprotection, cancer progression, and metabolic disorders. Its expression is regulated by dietary selenium levels, and dysregulation has been linked to neurodegenerative diseases (e.g., Alzheimer’s, Parkinson’s) and certain cancers.
SELENOM antibodies are critical tools for studying its expression, localization, and function. These antibodies are typically developed using recombinant SELENOM protein fragments or synthetic peptides containing immunogenic epitopes. Validation involves confirming specificity through Western blotting, immunohistochemistry (IHC), or knockout cell/animal models. Applications include investigating SELENOM’s role in oxidative stress pathways, ER stress modulation, and disease mechanisms. Recent studies highlight its potential as a biomarker or therapeutic target, driving demand for high-affinity, cross-reactive antibodies. Challenges remain in ensuring minimal cross-reactivity with other selenoproteins due to sequence homology. Commercial and custom SELENOM antibodies enable research into its interplay with selenium metabolism and disease pathogenesis, advancing our understanding of selenoprotein biology.